Cargando…

Pharmacist-led Smoking-Cessation Services in the United States – A Multijurisdictional Legal Analysis

A challenge presents itself when pharmacy students and pharmacists have the knowledge, skills, and abilities to provide optimal patient care, which can prevent the healthcare industry from incurring expenditures reaching billions of dollars annually from chronic and acute disease state management, y...

Descripción completa

Detalles Bibliográficos
Autores principales: Bordner, Landon S., Lavino, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: University of Minnesota Libraries Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598971/
https://www.ncbi.nlm.nih.gov/pubmed/36304682
http://dx.doi.org/10.24926/iip.v13i1.4643
_version_ 1784816480290865152
author Bordner, Landon S.
Lavino, Joseph
author_facet Bordner, Landon S.
Lavino, Joseph
author_sort Bordner, Landon S.
collection PubMed
description A challenge presents itself when pharmacy students and pharmacists have the knowledge, skills, and abilities to provide optimal patient care, which can prevent the healthcare industry from incurring expenditures reaching billions of dollars annually from chronic and acute disease state management, yet due to the lack of statutory or regulatory authority to independently prescribe and dispense smoking cessation products they are unable to tap into this potential. Prescriptive authority of pharmacists is not a novel concept; however, State Legislatures and Boards of Pharmacy have been slow to expand upon the pharmacist’s scope of practice to include this authority. As a consequence, this inaction hinders the opportunity of almost 21.5 million patients, who attempt to quit smoking annually, the ability to access a U.S. Food and Drug Administration approved, evidence-based medication-assisted or nicotine replacement therapy prescribed by a pharmacist.(2) Current legislative efforts, laws, and regulations regarding a pharmacist’s prescriptive authority for tobacco cessation therapy vary greatly amongst the states and do not include reference to e-cigarettes or electronic nicotine delivery systems (e.g., e-cigs, vape pens, vapes, mods, etc.). Additionally, pharmacists are often required to practice under a statewide protocol or enter into a collaborative practice agreement (“CPA”) with a designated physician, which are often complex and create significant barriers for the pharmacist to practice at the top of their license and for the benefit of the patient. This legal and regulatory study reveals the following: 1) Those States that have addressed or attempted to address the pharmacist’s prescriptive authority for tobacco cessation therapy, 2) the authority to independently prescribe vs. practice under a statewide protocol, 3) the products able to be prescriber or dispensed under the pharmacist’s prescriptive authority or statewide protocol, and 4) the guidelines and/or protocols referenced within their respective State laws and regulations. States and their residents would benefit greatly from amending their laws and regulations to expand upon the pharmacist’s prescriptive authority, granting them the ability to help their communities by performing services they are highly trained to perform.
format Online
Article
Text
id pubmed-9598971
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher University of Minnesota Libraries Publishing
record_format MEDLINE/PubMed
spelling pubmed-95989712022-10-26 Pharmacist-led Smoking-Cessation Services in the United States – A Multijurisdictional Legal Analysis Bordner, Landon S. Lavino, Joseph Innov Pharm Commentary A challenge presents itself when pharmacy students and pharmacists have the knowledge, skills, and abilities to provide optimal patient care, which can prevent the healthcare industry from incurring expenditures reaching billions of dollars annually from chronic and acute disease state management, yet due to the lack of statutory or regulatory authority to independently prescribe and dispense smoking cessation products they are unable to tap into this potential. Prescriptive authority of pharmacists is not a novel concept; however, State Legislatures and Boards of Pharmacy have been slow to expand upon the pharmacist’s scope of practice to include this authority. As a consequence, this inaction hinders the opportunity of almost 21.5 million patients, who attempt to quit smoking annually, the ability to access a U.S. Food and Drug Administration approved, evidence-based medication-assisted or nicotine replacement therapy prescribed by a pharmacist.(2) Current legislative efforts, laws, and regulations regarding a pharmacist’s prescriptive authority for tobacco cessation therapy vary greatly amongst the states and do not include reference to e-cigarettes or electronic nicotine delivery systems (e.g., e-cigs, vape pens, vapes, mods, etc.). Additionally, pharmacists are often required to practice under a statewide protocol or enter into a collaborative practice agreement (“CPA”) with a designated physician, which are often complex and create significant barriers for the pharmacist to practice at the top of their license and for the benefit of the patient. This legal and regulatory study reveals the following: 1) Those States that have addressed or attempted to address the pharmacist’s prescriptive authority for tobacco cessation therapy, 2) the authority to independently prescribe vs. practice under a statewide protocol, 3) the products able to be prescriber or dispensed under the pharmacist’s prescriptive authority or statewide protocol, and 4) the guidelines and/or protocols referenced within their respective State laws and regulations. States and their residents would benefit greatly from amending their laws and regulations to expand upon the pharmacist’s prescriptive authority, granting them the ability to help their communities by performing services they are highly trained to perform. University of Minnesota Libraries Publishing 2022-04-02 /pmc/articles/PMC9598971/ /pubmed/36304682 http://dx.doi.org/10.24926/iip.v13i1.4643 Text en © Individual authors https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License, which permits noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Bordner, Landon S.
Lavino, Joseph
Pharmacist-led Smoking-Cessation Services in the United States – A Multijurisdictional Legal Analysis
title Pharmacist-led Smoking-Cessation Services in the United States – A Multijurisdictional Legal Analysis
title_full Pharmacist-led Smoking-Cessation Services in the United States – A Multijurisdictional Legal Analysis
title_fullStr Pharmacist-led Smoking-Cessation Services in the United States – A Multijurisdictional Legal Analysis
title_full_unstemmed Pharmacist-led Smoking-Cessation Services in the United States – A Multijurisdictional Legal Analysis
title_short Pharmacist-led Smoking-Cessation Services in the United States – A Multijurisdictional Legal Analysis
title_sort pharmacist-led smoking-cessation services in the united states – a multijurisdictional legal analysis
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598971/
https://www.ncbi.nlm.nih.gov/pubmed/36304682
http://dx.doi.org/10.24926/iip.v13i1.4643
work_keys_str_mv AT bordnerlandons pharmacistledsmokingcessationservicesintheunitedstatesamultijurisdictionallegalanalysis
AT lavinojoseph pharmacistledsmokingcessationservicesintheunitedstatesamultijurisdictionallegalanalysis